Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Gusacitinib (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Sponsors Asana BioSciences
- 22 Apr 2023 Results of a Randomized Phase 2 Study assessing efficacy and safety published in the Journal of the American Academy of Dermatology
- 22 Apr 2021 According to an Asana BioSciences media release, positive results from this study will be presented in a late-breaking research program at the American Academy of Dermatology Virtual Meeting (AAD VMX 2021).
- 20 Oct 2020 According to an Asana BioSciences Media Release, gusacitinib was also effective in patients with chronic foot eczema and atopic dermatitis (as measured by vIGA in CHE patients who also had AD involvement) in this study and it demonstrated significant improvement in overall work productivity impairment. These results will be presented at a future date.